Keywords: پرالاتراکسات; AICA; 5-aminoimidazole-4-carboxamide; AICARFTase; 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; CA; carbonic anhydrase; CBE; CI-HCO3â exchanger; CHO; Chinese hamster ovary; FR; folate receptor; GARFTase; β-glycinamide ribonucleotide
مقالات ISI پرالاتراکسات (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پرالاتراکسات; Methotrexate; Pralatrexate; Dihydrofolate reductase; Folate; Folic acid; Purine synthesis; S phase; Apoptosis;
Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Keywords: پرالاتراکسات; ARGX-110; Brentuximab vedotin; Bortezomib; Copanlisib; cutaneous T-cell lymphoma; Forodesine; Gemcitabine; HDAC inhibitors; Ipilimumab; IPH4102; Mogamulizumab; Nivolumab; NM-IL-12; Panobinostat; Pegylated liposomal doxorubicin; Pentostatin; Pralatrexate;
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Keywords: پرالاتراکسات; Alisertib; ARGX-110; Belinostat; Bendamustine; Brentuximab vedotin; Copanlisib; Duvelisib; Gemcitabine; Lenalidomide; Mogamulizumab; Peripheral T-cell lymphoma; Pralatrexate; Refractory; Relapsed; Romidepsin; Selinexor;
Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Keywords: پرالاتراکسات; Peripheral T-cell lymphoma (PTCL); Histone deacetylase (HDAC) inhibitors; Pralatrexate; Epigenetic; Antibody drug conjugates;
Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas
Keywords: پرالاتراکسات; Adult T-cell leukemia/lymphoma; Anaplastic large cell lymphoma; Angioimmunoblastic T-cell lymphoma; Belinostat; Brentuximab vedotin; Peripheral T-cell lymphoma; Pralatrexate; Romidepsin;
Identification and characterization of forced degradation products of pralatrexate injection by LC-PDA and LC-MS
Keywords: پرالاتراکسات; Pralatrexate; Degradation products; Forced degradation; LC-MS; LC-PDA;
Treatment strategies for peripheral T-cell lymphomas
Keywords: پرالاتراکسات; peripheral T cell lymphoma; angioimmunoblastic T-cell lymphoma; HTLV-1 associated T cell lymphoma; enteropathy associated T-cell lymphoma; panniculitis-like T-cell lymphoma; monoclonal antibodies; denileukin diftitox; brentuximab vedotin; pralatrexate; hi
Lack of Expression of MTAP in Uncommon T-Cell Lymphomas
Keywords: پرالاتراکسات; Methylthioadenosine phosphorylase; Peripheral T-cell lymphoma; Pralatrexate
Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy
Keywords: پرالاتراکسات; antifolate; non–small-cell lung cancer; pralatrexate; survival
The Antifolates
Keywords: پرالاتراکسات; Methotrexate; Pralatrexate; Pemetrexed; Antifolates; Reduced folate carrier (RFC); Proton-coupled folate transporter (PCFT); Folate receptors; Folate receptor-mediated endocytosis;
Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial
Keywords: پرالاتراکسات; Pralatrexate; Antifolate; Non-small cell lung cancer; NSCLC; Dose-finding
New Strategies to Optimize Outcomes in Patients With T-Cell Lymphoma
Keywords: پرالاتراکسات; Aggressive B-cell lymphoma; CHOP therapy; CTCL; Pralatrexate; Methotrexate;
New Drugs for the Treatment of Lymphoma
Keywords: پرالاتراکسات; New drugs; Bcl-2; Lymphoma; Syk; Pralatrexate;
Phase II Trial of Pralatrexate (10-Propargyl-10-deazaaminopterin, PDX) in Patients with Unresectable Malignant Pleural Mesothelioma
Keywords: پرالاتراکسات; Pralatrexate; 10-Propargyl-10-deazaaminopterin; PDX; Mesothelioma; Antifolate;